News 12 February 2024 Launch of ANDROMEDA 2.0 ANDROMEDA 2.0 will be launched on Feb 15th. Welcome to attend our release event in… Urban Fagerholm
News 10 July 2023 PROSILICO is happy to announce a strategic partnership with Phenaros Pharmaceuticals PROSILICO is happy to announce a strategic partnership with Phenaros Pharmaceuticals (https://www.phenaros.com/). Together, we will… Urban Fagerholm
News 13 June 2023 PROSILICO will attend and present at 2 conferences PROSILICO will attend and present at Biotech Hanse in Stockholm and RSC Anglo-Nordic Medicinal Chemistry… Urban Fagerholm
News 22 May 2023 PROSILICO attended IDDST in Tokyo and presented new results PROSILICO attended IDDST in Tokyo 8-10 May and gave an oral presentation of new ANDROMEDA… Urban Fagerholm
News 21 March 2023 ANDROMEDA by Prosilico outperforms laboratory methods In 49 study comparisons, ANDROMEDA by Prosilico outperformed laboratory methods in 74 % of cases… Urban Fagerholm
News 21 March 2023 PROSILICO participates in the planned SciLifeLab PULSE cofund postdoctoral programme PROSILICO participates in the planned SciLifeLab PULSE cofund postdoctoral programme SciLifeLab has the ambition to… Urban Fagerholm
News 14 November 2022 New article and ANDROMEDA milestone- Successful validation Validation of predicted conformal intervals for prediction of human clinical pharmacokinetics https://www.biorxiv.org/content/10.1101/2022.11.10.515917v1 Urban Fagerholm
News 10 October 2022 New article – Successful use of ANDROMEDA in cases where labs fail ANDROMEDA by Prosilico software successfully predicts human clinical pharmacokinetics of 70 drugs out of reach… Urban Fagerholm
News 3 October 2022 Steps in the right direction! FDA Modernization Act - The bill defines “nonclinical tests or studies ” as a test… Urban Fagerholm